Risk stratification of patients with early stage breast cancer may support adjuvant chemotherapy decision-making. This review details the development and validation of six multi-gene classifiers, each of which claims to provide useful prognostic and possibly predictive information for early stage breast cancer patients. A careful assessment is presented of each test's analytical validity, clinical validity, and clinical utility, as well as the quality of evidence supporting its use.
Keywords: adjuvant; biomarkers; breast neoplasms; chemotherapy; clinical decision-making; gene expression; genomics risk; prognosis; tumor.
© 2017 The Authors. Journal of Surgical Oncology Published by Wiley Periodicals, Inc.